2903-45-9

Basic information

• Product Name: lignocaine N-oxide
• Synonyms: lignocaine N-oxide;Lidocaine N-Oxide;2-(DiethylaMino)-2',6'- acetoxylidide N-Oxide;2-(DiethylaMino)-N-(2,6-diMethylphenyl)acetaMide N2-Oxide;2-(DiethyloxidoaMino)-N-(2,6-diMethylphenyl)acetaMide;Lidocaine IMpurity B (Lidocaine N-Oxide);Lidocaine EP Impurity B;2-((2,6-dimethylphenyl)amino)-N,N-diethyl-2-oxoethanamine oxide
• CAS NO: 2903-45-9
• Molecular Formula: C₁₄H₂₂N₂O₂
• Molecular Weight: 250.33668
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 2903-45-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 127-129°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Storage Temp.: -20?C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 12.35±0.70(Predicted)
• CAS DataBase Reference: lignocaine N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: lignocaine N-oxide(2903-45-9)
• EPA Substance Registry System: lignocaine N-oxide(2903-45-9)

Safety Data

• Hazardous Substances Data: 2903-45-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

A novel metabolite of Lidocaine (L397800).

InChI:InChI=1/C14H22N2O2/c1-5-16(18,6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)

Upstream product

• 73-78-9 lidocaine hydrochloride 
• 137-58-6 2-diethylamino-N-(2,6-dimethylphenyl)-acetamide 

Relevant articles and documents

Oxidation-assisted structural elucidation of compounds containing a tertiary amine side chain using liquid chromatography mass spectrometry

A novel analytical technique for the structural elucidation of compounds bearing a tertiary amine side chain via “in vial” instantaneous oxidation and liquid chromatography mass spectrometry (LC-MS) was developed. A series of lidocaine homologs and benzimidazole derivatives with a major/single amine representative base peak in both their EI-MS and ESI-MS/MS spectra were subjected to oxidation by a 0.1% solution of hydrogen peroxide (including several 16O/18O exchange experiments), followed by LC-ESI-MS/MS analysis. The N-oxide counterparts promoted extensive fragmentation with complete coverage of all parts of the molecule, enabling detailed structural elucidation and unambiguous identification of the unoxidized analytes at low nanogram per milliliter levels.

FORMULATIONS OF N-OXIDE PRODRUGS OF LOCAL ANESTHETICS FOR THE TREATMENT OF PULMONARY INFLAMMATION ASSOCIATED WITH ASTHMA, BROCHITIS, AND COPD

A prodrug of lidocaine and related local anesthetic composition or formulation for delivery by aerosolization is described. The formulation containing an efficacious amount of lidocaine N-oxide prodrug or local anesthetic N-oxide prodrug able to inhibit i

In-vitro metabolism of lignocaine to its N-oxide

-